Study links pioglitazone to reduced MI risk in diabetes

Chinese researchers recruited 71,783 adults with type 2 diabetes and found that those who used pioglitazone had a 39% lower risk for myocardial infarction and a nonsignificant reduction in heart failure risk, compared with nonusers of pioglitazone. The findings in the Journal of Diabetes revealed that the pioglitazone group also had lower incidence rates for MI, heart failure and stroke than the non-pioglitazone group.